Follows people with plasma cell disorders in a hospital cohort study
Collects health records and samples from hospitalized patients with plasma cell disorders over time.
Plain-language title generated from the registry record
Registry title: A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for hospitalized patients at Peking University First Hospital with a confirmed plasma cell disorder who sign the consent form.
- Sex
- All sexes can join.
- Disease stage
- A confirmed plasma cell disorder, such as multiple myeloma, smoldering myeloma, MGUS, amyloidosis, plasma cell leukemia, Castleman's disease, POEMS syndrome or cryoglobulinemia.
Main reasons for not taking part
- A significant other illness that may be life-threatening
Read by machine on 9 November 2026.
Where in China
- Peking University First HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT05283993
- Record updated
- 16 September 2026
- Original description
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.Read full original descriptionShow less
A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.
Inclusion: Patients included are those with confirmed diagnosis of PCDs and hospitalized into Peking University First Hospital (PKUFH); Patients of plasma cell disorders (PCDs) are recruited. PCDs include monoclonal gammopathy of uncertain significance; smoldering myeloma; multiple myeloma; plasma cell leukemia; amyloidosis; light chain deposition disease; heavy chain deposition disease; Castleman's disease (CD); Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes syndrome; cryoglobulinemia; Monoclonal Gammopathy of Renal Significance (MGRS); Monoclonal gammopathy of neurological significance (MGNS); Patients are included into this cohort after signing the ICFs.
Exclusion: Significant comorbidity may be life-threatening.